Drug Profile
Research programme: beta-catenin responsive transcription inhibitors - ibeCa Thearpeutics
Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator New York University School of Medicine
- Class Antineoplastics; Oxazoles; Small molecules; Thiazoles
- Mechanism of Action Beta catenin inhibitors; Transcription factor inhibitors; Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for research development in Cancer in USA
- 16 Mar 2016 Early research in Cancer in USA (unspecified route)
- 16 Mar 2016 ibeCa Therapeutics acquires worldwide license to develop beta-catenin responsive transcription inhibitors from New York University School of Medicine